Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PREMIER Biosoft and JEOL Enter Agreement

Published: Thursday, June 06, 2013
Last Updated: Thursday, June 06, 2013
Bookmark and Share
The co-marketing agreement aims to advance research involving marker studies, drug metabolite profiling, lipid and proteomics analysis using MALDI-IMS technology.

PREMIER Biosoft and JEOL announce that they have signed a co-marketing agreement for MALDIVision, a MALDI Imaging Mass Spectrometry (MALDI IMS) data analysis tool. The collaboration aims to provide a comprehensive tool for advancing research involving marker studies, drug metabolite profiling, lipid and proteomics analysis using MALDI-IMS technology. Under this agreement, JEOL will promote MALDIVision along with its JMS-S3000 SpiralTOF™ Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometer.

MALDIVision visualizes and analyzes spatial distribution of analytes in a sampled tissue section. MALDIVision is the only tool on the market to seamlessly load and analyze imaging data files up to 20 GB. The program generates high quality reconstituted MALDI images in 2D and 3D based on the m/z value of target compounds. Users can overlay up to 10 MALDI images for visualization of spatial distribution of different compounds present in a sample.

According to Yoshihisa Ueda, the general manager of the Mass Spectrometry Business Unit JEOL Ltd., “Our JMS-S3000 SpiralTOF™ has the highest mass resolving power among any MALDI-TOFMS on the market. This imposes a unique challenge to the imaging data analysis software; the amount of information and, thus, the size of the imaging data from SpiralTOF is also the largest. After rigorous evaluation, we found that MALDIVision can process such data flawlessly. We are quite excited that, by combining SpiralTOF and MALDIVision, now we can offer a powerful and unique solution for the cutting edge research in life science and material science.”

“Mass Spectrometry is a rapidly growing platform for biomarker discovery. This collaboration will provide the research community, especially in the Asia-Pacific region, with a powerful tool to support mass spectrometry based imaging applications,” said Arun Apte, CEO at PREMIER Biosoft.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PREMIER Biosoft Announces Collaboration with University of Utah
Formal collaboration to advance metabolomics and lipidomics research.
Friday, August 07, 2015
PREMIER Biosoft Wins CIOReview's "Company of the Year" Award
"Company of the Year" award for the year 2014 in the life science category.
Thursday, February 19, 2015
PREMIER Biosoft Announce Successful Delivery of OligoArchitect™ Online v4.0 to Sigma-Aldrich
As a part of its contract software development services, PREMIER Biosoft has delivered OligoArchitect™ Online v4.0 to Sigma Life Science.
Thursday, September 05, 2013
Scientific News
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
The Epigenetics of Childhood Cancer
Qlucore software enables researchers to more easily study the genetic influences behind childhood cancer.
Mining Whole Exome Data to Improve Cancer Therapies
New tool interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!